BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.67
−0.74%Institutional positioning
13F filings over the trailing two quarters
New 3Increased 1Reduced 5Sold out 14
| Filer | Action | Shares | Filed |
|---|---|---|---|
| CITADEL ADVISORS LLC | New Position | 14,796 | Sep 2, 2026 |
| XTX TOPCO LTD | New Position | 10,941 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | New Position | 10,200 | May 15, 2026 |
| RHUMBLINE ADVISERS | Reduced | 2,353 | May 12, 2026 |
| BNP PARIBAS ARBITRAGE, SNC | Increased | 1,800 | May 12, 2026 |
| WELLS FARGO & COMPANY/MN | Unchanged | 1,750 | Jul 8, 2026 |
| CITIGROUP INC | Reduced | 1,728 | May 11, 2026 |
| UBS GROUP AG | Reduced | 529 | May 5, 2026 |
| NEMES RUSH GROUP LLC | Unchanged | 250 | Apr 21, 2026 |
| NEWEDGE ADVISORS, LLC | Unchanged | 107 | Jun 3, 2026 |
| MORGAN STANLEY | Reduced | 100 | May 15, 2026 |
| ADVISOR GROUP HOLDINGS, INC. | Unchanged | 26 | May 15, 2026 |
| ROCKEFELLER CAPITAL MANAGEMENT L.P. | Reduced | 12 | May 14, 2026 |
| DANSKE BANK A/S | Unchanged | 2 | May 12, 2026 |
| Banque Cantonale Vaudoise | Unchanged | 1 | Apr 20, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings